SIMULATIONS PLUS INC
SLPNASDAQTrading Snapshot
- Day Range
- $18.08 – $18.49
- 52-Week Range
- $11.09 – $21.01
- Volume
- $4.56B
- Avg Volume
- $3.08B
- Shares Outstanding
- 20.2M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $79M
- Last Q Revenue
- $22M
- P/E Ratio
- 45.7
- P/S Ratio
- 4.5x
- EPS (TTM)
- $0.40
- Dividend Yield
- 0.00%
Why Investors Own SLP
- ✓High-growth profile — revenue up +35.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SIMULATIONS PLUS INC
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
